During his 26 year career at Gilead, Jim Myers held a number of senior executive roles including complete responsibility for all U.S. and global sales, marketing and all commercial operations.

Since leaving Gilead he has joined the board of a number of biotech companies on both sides of the Atlantic, including Pulmocide in the U.K. He is also President and CEO of IntraBio, an Oxford-based biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for rare and common neurological disorders.

 The US always remains a unique environment for biotech, med tech and pharma with different playing fields which have their own rules and guardrails. 

With the recent introduction of the Inflation Reduction Act (IRA) some fundamental rules are changing and will require a new approach to drug development to future maximize value creation. 

Jim Meyers (BCG Senior Advisor and former Gilead Chief Commercial Officer) will share an overview on U.S. drug market environment, introduce the BCG view on the IRA, and discuss what all of it means for drug development in the coming years.